BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2347057)

  • 1. Ifosfamide, methotrexate, and 5-fluorouracil: effective combination in resistant breast cancer.
    Gad-el-Mawla N; Hamza MR; Zikri ZK; Elserafi M; el-Khodari A; Khaled H; Gafaar R
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S85-6. PubMed ID: 2347057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ifosfamide, methotrexate, and 5-fluorouracil in advanced pretreated breast cancer.
    Becher R; Höfeler H; Kloke O; Kurschel E; Schilcher RB; Weinhardt O; Wandl U; Schmidt CG
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):56-9. PubMed ID: 2495568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ifosfamide, methotrexate and 5-fluorouracil for pretreated advanced breast cancer.
    Becher R; Höfeler H; Kloke O; May D; Wandl U; Niederle N; Richter R; Scheulen ME; Schmidt CG
    Oncology; 1991; 48(6):459-63. PubMed ID: 1749582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of metastatic breast cancer with the combination of ifosfamide, epirubicin and 5-fluorouracil.
    Ghavamzadeh A
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S66-8. PubMed ID: 2347052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG).
    Andersson M; Madsen EL; Overgaard M; Rose C; Dombernowsky P; Mouridsen HT
    Eur J Cancer; 1999 Jan; 35(1):39-46. PubMed ID: 10211086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.
    Langenbuch T; Mross K; Jonat W; Hossfeld DK
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S93-6. PubMed ID: 2347058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of ifosfamide in breast cancer.
    Hortobagyi GN
    Semin Oncol; 1992 Dec; 19(6 Suppl 12):36-41. PubMed ID: 1485173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
    Lamar RE; Greco FA; Johnson DH; Murphy PB; Hainsworth JD
    Cancer; 1994 Apr; 73(7):1842-8. PubMed ID: 8137208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
    Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
    J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
    Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
    J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil].
    Ruffert K
    Zentralbl Chir; 1998; 123 Suppl 5():156-8. PubMed ID: 10063603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose mitomycin and weekly low-dose doxorubicin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Colozza M; Tonato M; Grignani F; Davis S
    Cancer; 1988 Jul; 62(2):262-5. PubMed ID: 3383126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.
    Mariani G; Petrelli F; Zambetti M; Moliterni A; Fasolo A; Marchiano A; Valagussa P; Gianni L
    Clin Breast Cancer; 2006 Oct; 7(4):321-5. PubMed ID: 17092399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ifosfamide combination chemotherapy in advanced breast cancer.
    Schmid H; Kaufmann M; Grischke EM; Bastert G
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S71-3. PubMed ID: 2347055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential administration of doxorubicin and paclitaxel followed by cyclophosphamide, methotrexate and 5-fluorouracil combination (CMF) in women with metastatic breast cancer.
    Papadimitriou CA; Dimopoulos MA; Ampela C; Louvrou-Fertaki A; Anagnostopoulos A; Athanassiades P; Stamatelopoulos S; Keramopoulos A
    Oncology; 1998; 55(6):533-7. PubMed ID: 9778619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
    Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
    J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
    Smith IE; Powles TJ
    Oncology; 1993 Apr; 50 Suppl 1():9-15. PubMed ID: 8483562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of ifosfamide in the management of breast cancer.
    Gad-el-Mawla N
    Ann Oncol; 1992 Aug; 3 Suppl 3():21-3. PubMed ID: 1390313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.